Physician profile
Nathan E Pierce
NPI 1538453634
$3,784.01
in general payments reported to CMS, 2019-2025
15 companies · $956 in 2025
The $956 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $142 · 2021: $84.23 · 2022: $844 · 2023: $386 · 2024: $747 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $833.38 | 2022-2025 | |
| Stryker Corporation | $798.62 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Xpress Loprofile |
| Medtronic, INC. | $679.06 | 2022-2025 | Ligasure, Sinuva, Stealthstation S8 Platform |
| Acclarent, INC | $340.28 | 2019-2024 | Trudi Nav Cable, Relieva Tract |
| Neurent Medical Limited | $303.10 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Merz North America, INC. | $218.14 | 2019-2020 | |
| Optinose US, INC. | $146.80 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $137.78 | 2021-2022 | |
| Glaxosmithkline, LLC. | $90.14 | 2022-2023 | Nucala |
| Genzyme Corporation | $87.45 | 2019-2022 | |
| Smith+Nephew, INC. | $53.78 | 2020-2025 | Halo |
| Regeneron Healthcare Solutions, INC. | $45.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $18.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.10 | 2019 | |
| Intersect Ent, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.